Champions Oncology Inc (CSBR) FinancialsCSBRFinancialChampions Oncology Inc

Champions Oncology Inc (CSBR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmacology services, accounting for 93.7% of total sales, equivalent to $13.12M. Another important revenue stream is Other. Understanding this composition is critical for investors evaluating how CSBR navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Champions Oncology Inc maintains a gross margin of 50.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.77%, while the net margin is -4.82%. These profitability ratios, combined with a Return on Equity (ROE) of -30.48%, provide a clear picture of how effectively CSBR converts its operational activities into shareholder value.

In the context of the broader market, CSBR competes directly with industry leaders such as PLRX and XBIT. With a market capitalization of $68.91M, it holds a significant position in the sector. When comparing efficiency, CSBR's gross margin of 50.78% stands against PLRX's N/A and XBIT's N/A. Such benchmarking helps identify whether Champions Oncology Inc is trading at a premium or discount relative to its financial performance.

Champions Oncology reported record annual revenue of $59.4 million for fiscal 2026, but net income has been inconsistent, with losses in several quarters. The gross margin has varied, with a recent figure of 50.78% in Q4 2026, indicating some operational efficiency but also volatility in profitability.